Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 9/2003

01-09-2003 | Therapy in Practice

Optimal Treatment of Pyoderma Gangrenosum

Authors: Samuel L. Gettler, Dr Marti J. Rothe, Caron Grin, Jane M. Grant-Kels

Published in: American Journal of Clinical Dermatology | Issue 9/2003

Login to get access

Abstract

The optimal treatment of pyoderma gangrenosum includes a combination of local wound care and systemic medications. Oral and pulse intravenous corticosteroids have traditionally been the most commonly recommended first-line systemic therapies. Cyclosporine, with or without corticosteroids, has more recently emerged as a first-line systemic treatment. A multitude of immunosuppressive and immune-modulating medications, as well as antimicrobial agents with anti-inflammatory properties have also been widely prescribed. Often, it is difficult to achieve control of aggressive cases of pyoderma gangrenosum, necessitating administration of a combination of systemic therapies. Furthermore, patients recalcitrant to one or many medications are frequently reported. Concomitant disease, intolerance to a class of medications, and the patient’s response to prior therapies can help guide a practitioner in choosing the optimal treatment of pyoderma gangrenosum.
Footnotes
1
Use of tradenames is for product identification only and does not imply endorsement
 
Literature
1.
Brocq L. Nouvelle contribution a l’etude du phagedenisme geometrique. Ann Dermatol Syphiligr (Paris) 1916; 6: 1–39
2.
Brunsting LA, Goeckerman WH, O’Leary PA. Pyoderma (ecthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol 1930; 22: 655–80CrossRef
3.
Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission: case review of 86 patients from 2 institutions. Medicine 2000; 79 (1): 37–46PubMedCrossRef
4.
Powell FC, Su WPD, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996; 34 (3): 395–409PubMedCrossRef
5.
Lachapelle JM, Marot L, Jablonska S. Superficial granulomatous pyoderma gangrenosum of the face, successfully treated by ciclosporine: a long-term follow-up. Dermatology 2001; 202: 155–7PubMedCrossRef
6.
Von Den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997; 137: 1000–5PubMedCrossRef
7.
de Imus G, Golomb C, Wilkel C, et al. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Am Acad Dermatol 2001; 44 (1): 61–6PubMedCrossRef
8.
Phillips TJ, Bigby M, Bercovitch L. Cultured allografts as an adjunct to the medical treatment of problematic leg ulcers. Arch Dermatol 1991; 127: 799–801PubMedCrossRef
9.
Goldstein F, Krain R, Thornton JJ. Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol 1985; 7: 499–501PubMedCrossRef
10.
11.
Tamir A, Landau M, Brenner S. Topical treatment with 1% sodium cromoglycolate in pyoderma gangrenosum. Dermatology 1996; 192 (3): 252–4PubMedCrossRef
12.
Tsele E, Yu RCH, Chu AC. Pyoderma gangrenosum: response to topical nitrogen mustard. Clin Exp Dermatol 1992; 17: 437–40PubMedCrossRef
13.
Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 1998; 139: 738–59CrossRef
14.
Sanders CJG, Hulsmans RFHJ. Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis 1993; 51 (4): 262–4PubMed
15.
16.
Thomas CY, Crouch JA, Guastello J. Hyperbaric oxygen therapy for pyoderma gangrenosum. Arch Dermatol 1974; 110: 445–6PubMedCrossRef
17.
Davis JC, Landeen JM, Levine RA. Pyoderma gangrenosum: skin grafting after preparation with hyperbaric oxygen. Plastic Reconstr Surg 1987; 79: 200–6CrossRef
18.
Reynoso-von Drateln C, Perla-Navarro AV, Gamez-Nava JI, et al. Intravenous cyclophosphamide in pyoderma gangrenosum: an open trial. J Rheumatol 1997; 24 (4): 689–93PubMed
19.
Johnson RB, Lazarus GS. Pulse therapy: therapeutic efficacy in the treatment of pyoderma gangrenosum. Arch Dermatol 1982; 118: 76–84PubMedCrossRef
20.
21.
White KP, Driscoll MS, Rothe MJ, et al. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol 1994; 30 (5 Pt 1): 768–73PubMedCrossRef
22.
Cather JC, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin 2001; 19 (1): 119–37PubMedCrossRef
23.
Matis WL, Ellis CN, Griffiths CEM, et al. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992; 128: 1060–4PubMedCrossRef
24.
Curley RK, Macfarlane AW, Vickers CFH. Pyoderma gangrenosum treated with cyclosporin A. Br J Dermatol 1985; 113: 601–4PubMedCrossRef
25.
Kauvar AB, Stiller MJ. Cyclosporine in dermatology: pharmacology and clinical use. Int J Dermatol 1994; 33 (2): 86–96PubMedCrossRef
26.
Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39 (3): 464–75PubMedCrossRef
27.
Wolverton SE. Comprehensive dermatologic drug therapy. Philadelphia: WB Saunders, 2001
28.
29.
Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133: 1224–30PubMedCrossRef
30.
Wolverton SE, Wilkin JK. Systemic drugs for skin diseases. Philadelphia: WB Saunders, 1991
31.
Remicade® (infliximab) for IV injection. Physician’s Desk Reference. 57th edition. Montvale (NJ): Thomson PDR, 2003: 1178–82
32.
Weichert G, Sauder DN. Efficacy of tacrolimus (FK 506) in idiopathic treatment-resistant pyoderma gangrenosum. J Am Acad Dermatol 1998; 39 (4): 648–50PubMedCrossRef
33.
Abu-Elmagd K, Van Thiel DH, Jegasothy BV, et al. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med 1993; 119 (7 Pt 1): 595–8PubMed
34.
Lyon CC, Kirby B, Griffiths CEM. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. Br J Dermatol 1999; 140: 538–68CrossRef
35.
Hohenleutner U, Mohr VD, Michel S, et al. Mycophenolate mofetil and cyclosporine treatment for recalcitrant pyoderma gangrenosum [letter]. Lancet 1997; 350 (9053): 1748PubMedCrossRef
36.
Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000 Sep 27; 284 (12): 1546–8PubMedCrossRef
37.
Kitchin JES, Pomeranz MK, Pak G, et al. Rediscovering mycophenolic acid: a review of its mechanisms, side effects, and potential uses. J Am Acad Dermatol 1997; 37 (3): 445–9PubMedCrossRef
38.
Nousari HC, Lynch W, Anhalt GJ, et al. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998; 134 (12): 1509–11PubMedCrossRef
39.
Grandmann-Kollmann M, Podda M, Oschsendorf F, et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001 Jul; 137 (7): 870–3
40.
Dutz JP, Ho VC. Immunosuppressive agents in dermatology: an update. Dermatol Clin 1998 Apr; 16 (2): 235–51PubMed
41.
Byrne JPH, Hewitt M, Summerly R. Pyoderma gangrenosum associated with active chronic hepatitis. Arch Dermatol 1976; 112: 1297–301PubMedCrossRef
42.
Knowles SR, Gupta AK, Shear NH, et al. Azathioprine hypersensitivity-like reactions: a case report and review of the literature. Clin Exp Dermatol 1995; 20: 353–6PubMedCrossRef
43.
Tavadia SMB, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42 (4): 628–32PubMed
44.
Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis 1996; 57 (5): 326–8PubMed
45.
Zonana-Nacach A, Jimenez-Balderas FJ, Martinez-Osuna P, et al. Intravenous cyclophosphamide pulses in the treatment of pyoderma gangrenosum associated with rheumatoid arthritis: report of 2 cases and review of the literature. J Rheumatol 1994; 21: 1352–6PubMed
46.
Fox LP, Pandya AG. Pulse intravenous cyclophosphamide therapy for dermatologic disorders. Dermatol Clin 2000; 18: 459–73PubMedCrossRef
47.
Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol 1996; 35 (5): 720–4PubMedCrossRef
48.
Resnick BI, Rendon M, Kerdel FA. Successful treatment of aggressive pyoderma gangrenosum with pulse steroids and chlorambucil. J Am Acad Dermatol 1992; 27: 635–6CrossRef
49.
Moller H, Waldenstrom JG, Zettervall O. Pyoderma gangrenosum (dermatitis ulcerosa) and monoclonal (IgA) globulin healed after melphelan treatment: case report and review of the literature. Acta Med Scand 1978; 203: 293–6PubMedCrossRef
50.
Perry HO, Brunsting LA. Pyoderma gangrenosum: a clinical study of 19 cases. Arch Dermatol 1957; 75: 380–6CrossRef
51.
Lorincz AL, Pearson RW. Sulfapyridine and sulfone type drugs in dermatology. Arch Dermatol 1962; 85: 42–54CrossRef
52.
53.
Lynch WS, Bergfeld WF. Pyoderma gangrenosum responsive to minocycline hydrochloride. Cutis 1978; 21: 535–8PubMed
54.
Galun E, Flugelman MY, Rachmilewitz D. Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol 1986; 81: 988–9PubMed
55.
Michaelsson G, Molin L, Ohman S, et al. Clofazimine: a new agent for the treatment of pyoderma gangrenosum. Arch Dermatol 1976; 112: 344–9PubMedCrossRef
56.
Kaplan B, Trau H, Sofer E, et al. Treatment of pyoderma gangrenosum with clofazimine. Int J Dermatol 1992; 31 (8): 591–3PubMedCrossRef
57.
Boulinguez S, Bernard P, Bedane C, et al. Pyoderma gangrenosum complicating Cogan’s syndrome. Clin Exp Dermatol 1998; 23: 286–9PubMedCrossRef
58.
59.
Lugassy G, Ronnen M. Case report: severe pyoderma gangrenosum associated with familial mediterranean fever-favorable response to colchicine in three patients. Am J Med Sci 1992; 304: 29–31PubMedCrossRef
60.
Hecker MS, Lebwohl MG. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol 1998; 38 (3): 490–1PubMedCrossRef
61.
Buckley C, Sarkany I, Bayoum AHM. Pyoderma gangrenosum with severe pharyngeal ulceration. J R Soc Med 1990; 83: 590–1PubMed
62.
63.
System for thalidomide education and prescribing: safety instructions for prescribers. Celgene Corporation, 1998
64.
Dirschka T, Kastner U, Behrens S, et al. Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. J Am Acad Dermatol 1998; 39 (5): 789–90PubMedCrossRef
65.
Gupta AK, Shear NH, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol 1995; 32: 140–2PubMedCrossRef
66.
Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001; 44 (6): 1010–24PubMedCrossRef
67.
Smith JB, Shenefelt PD, Soto O, et al. Pyoderma gangrenosum in a patient with cryoglobulinemia and hepatitis C successfully treated with interferon alfa. J Am Acad Dermatol 1996; 34 (5): 901–3PubMedCrossRef
68.
Tan MH, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alfa monoclonal antibody. Arch Dermatol 2001; 137: 930–3PubMed
69.
Mimouni D, Anhalt GJ, Kouba DJ, et al. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003; 148: 813–6PubMedCrossRef
70.
Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-α blockade with infliximab. Scand J Gastroenterol 2002; 37: 1108–10PubMedCrossRef
71.
Triantafillidis JK, Cheracakis P, Sklavaina M, et al. Favorable reponse to infliximab treatment in a patient with Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 2002; 37: 863–5PubMed
72.
Grange F, Djilali-Bouzina F, Weiss AM, et al. Corticosteroid-resistant pyoderma gangrenosum associated Crohn’s disease: rapid cure with infliximab. Dermatology 2002; 205: 278–80PubMedCrossRef
Metadata
Title
Optimal Treatment of Pyoderma Gangrenosum
Authors
Samuel L. Gettler
Dr Marti J. Rothe
Caron Grin
Jane M. Grant-Kels
Publication date
01-09-2003
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 9/2003
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200304090-00002

Other articles of this Issue 9/2003

American Journal of Clinical Dermatology 9/2003 Go to the issue

Therapy in Practice

Botulinum Toxin A

Leading Article

Antimicrobial Peptides

Therapy in Practice

Itch Associated with Skin Disease

Review Article

Drug Interactions of Clinical Significance for the Dermatologist

Pharmacovigilance

Cutaneous Drug Reaction Case Reports

Review Article

Secondary Infections in Patients with Atopic Dermatitis